
Vabysmo(Faricimab-svoa) Instructions:Uses,Dosage, Side Effects
VABYSMO (faricimab-svoa) is a humanized bispecific immunoglobulin G1 antibody that inhibits both vascular endothelial growth factor A and angiopoietin-2. It is supplied as a sterile solution in single-dose prefilled syringes or vials for intravitreal use. The medication reduces endothelial cell proliferation and vascular permeability while promoting vascular stability, aiding in the management of retinal conditions. It is produced using recombinant DNA technology in mammalian cell culture.
